AI

FDA authorizes software to identify prostate cancer

The U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body).

The software, called Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

“Pathologists examine biopsies of tissue suspected for diseases, such as prostate cancer, every day. Identifying areas of concern on the biopsy image can help pathologists make a diagnosis that informs the appropriate treatment,” said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “The authorization of this AI-based software can help increase the number of identified prostate biopsy samples with cancerous tissue, which can ultimately save lives.”

The FDA reviewed the device through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through FDA’s 510(k) premarket process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization of the Paige Prostate software to Paige.AI.

23.09.2021

Read all latest stories

Related articles

Photo

Prostate cancer

Diagnosing cancer using a urine test with AI

Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on PSA, a cancer factor in blood. However, as diagnostic accuracy is as…

Photo

Oncology

How cancer spreads in blood

A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a…

Photo

Next generation diagnostics

Using AI to detect and grade prostate cancer

Researchers at Karolinska Institutet have developed a method based on artificial intelligence for histopathological diagnosis and grading of prostate cancer. The AI-system has the potential to solve…

Related products

Agfa - Smart XR

Accessories/ Complementary Systems

Agfa - Smart XR

Agfa HealthCare
Beckman Coulter – Prostate Health Index (phi)

Immunochemistry

Beckman Coulter – Prostate Health Index (phi)

Beckman Coulter, Inc.
Canon - Advanced Intelligent Clear-IQ Engine for CT

Artificial Intelligence

Canon - Advanced Intelligent Clear-IQ Engine for CT

Canon Medical Systems Europe B.V.
Canon – Advanced intelligent Clear-IQ Engine for MR

Artificial Intelligence

Canon – Advanced intelligent Clear-IQ Engine for MR

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon - HIT Automation Platform

Artificial Intelligence

Canon - HIT Automation Platform

Canon Medical Systems Europe B.V.
Subscribe to Newsletter